Active Ingredient History
Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon. Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases. However foralumab did not show efficacy for Crohn's disease. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
COVID-19 (Phase 2)
Crohn Disease (Phase 1)
Diabetes Mellitus, Type 2 (Phase 2)
Multiple Sclerosis (Phase 1)
Multiple Sclerosis, Chronic Progressive (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue